Taficure EM – Complete HIV Treatment Guide | Tenofovir Alafenamide & Emtricitabine

Taficure EM is a fixed-dose antiretroviral medication containing Tenofovir Alafenamide 25 mg and Emtricitabine 200 mg. Taficure EM is indicated for the treatment of HIV‑1 infection in adults and adolescents aged 12 years and older weighing at least 35 kg, as part of combination antiretroviral therapy (ART).

Quick Overview of Taficure EM

Composition & Mechanism of Action

• Tenofovir Alafenamide Hemifumarate IP equivalent to 25 mg
• Emtricitabine IP 200 mg
• Colouring Agents: Indigo Carmine & Titanium Dioxide

Tenofovir Alafenamide (TAF) is a nucleotide reverse transcriptase inhibitor that blocks HIV replication by inhibiting the viral reverse transcriptase enzyme.

Emtricitabine is a nucleoside reverse transcriptase inhibitor active against HIV‑1 and Hepatitis B Virus (HBV), preventing viral DNA synthesis.

Together, these agents form a potent NRTI backbone recommended under global HIV treatment guidelines including WHO and NIH.

Indications & Clinical Use of Taficure EM

Taficure EM is indicated in combination with other antiretroviral agents for:

• Treatment of HIV‑1 infection
• Adults
• Adolescents ≥12 years
• Body weight ≥35 kg

Taficure EM 200/10 mg has been studied with darunavir 800 mg and cobicistat 150 mg in treatment‑naïve patients.

For full product specifications visit:
Taficure EM – Generic Descovy Product Page

Dosage & Administration Guidelines

• Take Taficure EM once daily
• May be taken with or without food
• Do NOT crush, chew, or split tablet

Missed Dose Instructions

• If within 18 hours of usual time → Take immediately
• If more than 18 hours → Skip missed dose
• If vomiting occurs within 1 hour → Take another tablet

Special Population Guidance

Elderly

No dose adjustment required.

Renal Impairment

• No adjustment if CrCl ≥30 mL/min
• Do not initiate if CrCl <30 mL/min
• Discontinue if renal function declines below 30 mL/min

Hepatic Impairment

No dose adjustment required.

Paediatric Population

Safety and efficacy not established in children under 12 years or weighing less than 35 kg.

Safety Profile & Clinical Data

Safety evaluation includes Phase 2 and Phase 3 clinical trials involving 3,112 HIV‑1 infected patients receiving TAF and emtricitabine-containing regimens.

Common Adverse Reactions

• Nausea (11%)
• Diarrhoea (7%)
• Headache (6%)

HBV Co‑Infection Warning

Tenofovir alafenamide is active against HBV. Discontinuation in co‑infected patients may cause severe acute exacerbation of hepatitis. Monitor liver function closely.

Immune Reconstitution Syndrome (IRIS)

Inflammatory reactions to opportunistic infections may occur during early ART initiation.

Mitochondrial Dysfunction

Nucleos(t)ide analogues may impact mitochondrial function, particularly in infants exposed in utero.

HIV Prevention & PrEP Information

Although Taficure EM is indicated for HIV treatment, related formulations are used in prevention strategies such as Pre‑Exposure Prophylaxis (PrEP). Learn more in our detailed guide:

PrEP Medicine Guide – Taficure EM

HIV prevention strategies are supported by global authorities including CDC and UNAIDS.

Drug Interaction Profile

Clinical pharmacokinetic studies show low potential for CYP-mediated drug interactions involving Taficure EM components. Review concomitant medications prior to prescribing.

Overdose Management

If overdose occurs, monitor patient for toxicity. Provide supportive care including monitoring of vital signs and clinical status.

Storage & Handling

• Store below 30°C
• Protect from moisture and light
• Keep bottle tightly closed
• Refer to label for shelf life

Frequently Asked Questions (FAQ) About Taficure EM

Medical Review & Transparency

Medically Reviewed By: Licensed Medical Professional (MD – Infectious Diseases)

Last Updated: June 2026

Marketing Information

Marketed By:
Pinkline Exports
Shop No. 9, Jawahar Nagar Sector‑2
Jaipur, India – 302004